The DXP-604 experimental treatment is based on a single neutralising antibody identified from the plasma of 60 recovering Covid-19 patients. Photo: Shutterstock
The DXP-604 experimental treatment is based on a single neutralising antibody identified from the plasma of 60 recovering Covid-19 patients. Photo: Shutterstock

New Chinese Covid-19 antibody treatment shows promise, as China races to find a cure

  • Experimental neutralising antibody treatment able to tackle all variants shown to reduce viral loads and symptoms for 14 Beijing patients
  • The therapy fights mutations with a single antibody, which will help cut production costs by one third, an official newspaper reported

Topic |   Coronavirus pandemic
The DXP-604 experimental treatment is based on a single neutralising antibody identified from the plasma of 60 recovering Covid-19 patients. Photo: Shutterstock
The DXP-604 experimental treatment is based on a single neutralising antibody identified from the plasma of 60 recovering Covid-19 patients. Photo: Shutterstock
READ FULL ARTICLE